Biotech startups from the UK traditionally have a financing strategy that leads to one of two places – the NASDAQ or the NYSE. This means learning how to follow a US-centric playbook. About 10 percent of the biotech IPOs on the US markets this year come from companies based outside the US. This is consistent with trends of the past... Read More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
I first met Ken Frazier, the CEO of Merck, at the JP Morgan Healthcare Conference in San Francisco in January 2018. It was my second year as an operator in biotech. I was still getting familiar with the whole bewildering experience of JPM. I was trained as a cancer immunologist at Dartmouth, did a stint in life sci strategy consulting,... Read More